Answers are grounded in this paper and cite their sources.
IFN-γ is a central effector node in immunotherapy. Recent studies suggest that the actual function of IFN-γ signaling depends on the combined effects of exposure duration, concentration gradient, glioblastoma (GBM) molecular subtype, and tumor microenvironment (TME) cellular composition, rather than on an intrinsic property of the cytokine itself. In GBM, chronic IFN-γ exposure drives lineage-dependent adaptive reprogramming, with mesenchymal-like and proneural-like cells exhibiting distinct patterns of signaling adaptation. These findings challenge a binary view of IFN-γ function and suggest that therapeutic strategies may need to extend beyond simple activation or blockade of this pathway.IFN-γ also influences macrophage polarization, regulatory T-cell function, NK-cell subset responses, and the expansion of myeloid-derived suppressor cells, while modulating antigen presentation, immunosuppression, and metabolic reprogramming within the TME. Together, these actions position IFN-γ as a convergence point bridging therapeutic response and adaptive resistance. However, the limited clinical efficacy of recombinant IFN-γ in GBM highlights the need for a more precise understanding of the temporal and context-dependent regulation of IFN-γ signaling. Strategies targeting IFN-γ-associated resistance mechanisms, including TNFRSF14 or JAK-STAT signaling and impaired NK-cell function, have been explored; however, a clear therapeutic rationale or contextual framework for targeting these pathways has yet to be established.Defining how IFN-γ switches between antitumor and protumor functions across GBM subtypes and treatment contexts may therefore be critical for the rational design of combination immunotherapies. In this review, we synthesize current evidence on IFN-γ signaling, its direct effects on GBM cells, its regulation of the immune microenvironment, and its translational implications, and propose a context-dependent framework for therapeutically targeting this pathway.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: